Evren Technologies, Inc., a leading innovator in neuromodulation medical devices for PTSD, is pleased to announce that Rick Giancola, Evren’s President & CEO, has joined its Board of Directors. With over 35 years of experience in the life sciences and neuromodulation industries, Mr. Giancola brings a wealth of knowledge and a proven track record of business development and strategic growth success to this role.
Mr. Giancola is passionate about neuromodulation technology and its powerful ability to transform lives. As the Owner and Managing Director of Otomed Consulting, LLC, he has advised global leaders, emerging companies, venture capital, and investment firms in the life sciences space on business development and operational systems of neuromodulation devices. His work includes novel tinnitus treatments, hearing implants, and innovative approaches for other neurological disorders.
At Cochlear Americas, Mr. Giancola's team built the Latin American business, growing revenue by 30% year-over-year and establishing Latin America as a key component of Cochlear’s global strategy. He then joined Neuromonics, Inc. as CEO (later acquired by SoundVida) and bone conduction hearing pioneer Sophono (acquired by Medtronic). As Executive Vice President of the Americas/EMEA at Nurotron Biotechnology, Inc., Mr. Giancola drove significant growth by heading all commercial, clinical, research, regulatory, education, and training activities for the Americas, Europe, the Middle East, and Africa. His strategic initiatives resulted in a fivefold increase in sales in Latin America and EMEA in these diverse global markets.
“We are delighted to welcome Rick Giancola to our Board of Directors,” said Weaver Gaines, Chairman of the Board. “Rick's extensive experience in neuromodulation, his operating expertise and strategic vision, and his ability to make forward progress in a resource-constrained environment will be invaluable as we continue to innovate and expand our presence in the field of noninvasive neuromodulation for PTSD.”
Mr. Giancola joins a world-class board of directors featuring esteemed members such as Richard Ferrari, Stephanie Warrington, and Suha Jhaveri. Their collective expertise and leadership in the medical device and life sciences industries will be instrumental in guiding Evren towards its mission of transforming the treatment of PTSD, stress, and related disorders.
In addition to his board role, Mr. Giancola will lead the fundraising efforts needed to conduct the FDA pivotal trial for Evren's first commercial product, the Phoenix® 100. His leadership and experience in capital acquisition will be crucial in advancing the development and commercialization of this groundbreaking PTSD treatment. In 2023, Evren launched the Phoenix CR, a research device that administers transcutaneous auricular VNS (taVNS) safely and effectively in laboratory, clinical, and unsupervised home settings for VNS research under IRB control.
About Evren Technologies
Evren is a bioelectronic medical device company in the field of neuromodulation devices and is transforming the treatment of PTSD, Acute Stress Reactions, Acute Stress Disorder, and Adjustment Disorders by delivering noninvasive, breakthrough, Vagal Nerve Stimulation (VNS) to the auricular branch of the vagus nerve.
Our initial product -- the Phoenix® CR – administers transcutaneous auricular VNS (taVNS) safely and effectively in laboratory, clinical, and unsupervised home settings for VNS research use and was launched in late 2023. The Phoenix CR will also be the clinical trial device in Evren’s pivotal trial seeking De Novo classification from the FDA. It will deliver safe and effective taVNS therapy, with no known adverse side effects.
Bioelectronic medicine uses sophisticated technology to modulate the electrical activity of the body’s nervous system and has the potential to supplement or even replace drugs or other interventions. Evren’s technology is based on stimulating the vagus nerve, the main nerve of the parasympathetic (“calming or safety”) branch of the autonomic nervous system.
For further information about the Phoenix CR or Evren Technologies, please visit evrenvns.com.
CONTACT:
Josh Kelly, Director of Operations
Evren Technologies, Inc.
904.517.2432
Comments